Frequency and prognostic impact of alk amplifications and mutations in the european neuroblastoma study group (siopen) high-risk neuroblastoma trial (hr-nbl1)

  1. Bellini, A.
  2. Potschger, U.
  3. Bernard, V.
  4. Lapouble, E.
  5. Baulande, S.
  6. Ambros, P.F.
  7. Auger, N.
  8. Beiske, K.
  9. Bernkopf, M.
  10. Betts, D.R.
  11. Bhalshankar, J.
  12. Bown, N.
  13. De Preter, K.
  14. Clement, N.
  15. Combaret, V.
  16. De Mora, J.F.
  17. George, S.L.
  18. Jimenez, I.
  19. Jeison, M.
  20. Marques, B.
  21. Martinsson, T.
  22. Mazzocco, K.
  23. Morini, M.
  24. Muhlethaler-Mottet, A.
  25. Noguera, R.
  26. Pierron, G.
  27. Rossing, M.
  28. Taschner-Mandl, S.
  29. Van Roy, N.
  30. Vicha, A.
  31. Chesler, L.
  32. Balwierz, W.
  33. Castel, V.
  34. Elliott, M.
  35. Kogner, P.
  36. Laureys, G.
  37. Luksch, R.
  38. Malis, J.
  39. Popovic-Beck, M.
  40. Ash, S.
  41. Delattre, O.
  42. Valteau-Couanet, D.
  43. Tweddle, D.A.
  44. Ladenstein, R.
  45. Schleiermacher, G.
  46. Show all authors +
Journal:
Journal of Clinical Oncology

ISSN: 1527-7755 0732-183X

Year of publication: 2021

Volume: 39

Issue: 30

Pages: 3377-3390

Type: Article

DOI: 10.1200/JCO.21.00086 GOOGLE SCHOLAR lock_openOpen access editor